Clinical trials have shown that Mosquirix provides partial protection against malaria. It has been observed to reduce the occurrence of malaria by about 39% in children who received four doses of the vaccine. While this may not seem highly effective, it is significant given the high burden of malaria in affected regions. The efficacy of the vaccine varies with age and declines over time, necessitating booster doses.
